<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795141</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-035-204</org_study_id>
    <nct_id>NCT04795141</nct_id>
  </id_info>
  <brief_title>ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmagene Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inmagene Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing&#xD;
      spondylitis(AS). The primary objective is to estimate the relationship between different dose&#xD;
      regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis&#xD;
      International Society 40 (ASAS40) response at Week 16 in subjects with active AS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABY-035-204 is a double-blind, randomized, parallel-group, placebo-controlled study.&#xD;
&#xD;
      The primary objective is to estimate the relationship between different dose regimens of&#xD;
      ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International&#xD;
      Society 40 (ASAS40) response at Week 16 in subjects with active AS.&#xD;
&#xD;
      The study will include the following 3 periods:&#xD;
&#xD;
        1. Screening Period: Up to 35 days prior to baseline randomization.&#xD;
&#xD;
        2. Treatment Period 1: Day 0-Week 16 Eligible subjects will be randomized 1:1:1:1 to&#xD;
           receive 1 of 4 treatments (ABY-035 80 mg Q2W, ABY-035 160 mg Q4W, ABY-035 40 mg Q2W, or&#xD;
           placebo).&#xD;
&#xD;
           Treatment Period 1 ends at Week 16 after all trial assessments have been done and&#xD;
           Treatment Period 2 starts at Week 16 with the IMP injection.&#xD;
&#xD;
        3. Treatment Period 2 (Extension Period): Week 16-Week 52 Subjects will continue their&#xD;
           original treatment of Treatment Period 1 in a double-blinded manner.&#xD;
&#xD;
      Subjects who could not achieve an ASAS20 response from baseline are defined as non-responders&#xD;
      and eligible for rescue treatment after Week 16 (Visit 9).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 26, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment Period 1: Day 0-Week 16 Eligible subjects will be randomized 1:1:1:1 to receive 1 of 4 treatments (ABY-035 80 mg Q2W, ABY-035 160 mg Q4W, ABY-035 40 mg Q2W, or placebo), and will remain on their allowable background medication.&#xD;
Treatment Period 1 ends at Week 16 after all trial assessments have been done and Treatment Period 2 starts at Week 16 with the IMP injection.&#xD;
Treatment Period 2 (Extension Period): Week 16-Week 52 Subjects will continue their original treatment of Treatment Period 1 in a double-blinded manner.&#xD;
Subjects who could not achieve an ASAS20 response from baseline are defined as non-responders and eligible for rescue treatment after Week 16 (Visit 9).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving an ASAS40 response</measure>
    <time_frame>16 weeks</time_frame>
    <description>The treatment effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BASDAI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BASFI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reaching ASDAS-MI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>74 weeks</time_frame>
    <description>Safety information</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>74 weeks</time_frame>
    <description>Safety information</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs leading to withdrawal from investigational medicinal product (IMP)</measure>
    <time_frame>74 weeks</time_frame>
    <description>Safety information</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving an ASAS40 response at Week 2, 24 and 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BASDAI at Week 2, 24 and 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BASFI at Week 2, 24 and 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reaching ASDAS-MI at Week 24 and 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The treatment effect</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80mg ABY-035 Q2W SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160mg ABY-035 Q4W SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg ABY-035 Q2W SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Q2W SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABY-035</intervention_name>
    <description>ABY-035 80 mg Q2W, 160 mg Q4W, 40 mg Q2W; Duration: 52 weeks</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Izokibep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Dosage form: Solution for injection; Dosage and frequency: Isotonic saline solution (0.9% sodium chloride),Q2W; Duration: 52 weeks</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female at least 18 years of age.&#xD;
&#xD;
          2. Subjects with active AS, determined by documented radiologic evidence (X-ray)&#xD;
             fulfilling the Modified New York criteria for AS (1984).&#xD;
&#xD;
             AND At least one SpA feature, according to ASAS criteria.&#xD;
&#xD;
          3. Subjects have moderate to severe active disease&#xD;
&#xD;
          4. Subjects must have inadequate response or intolerance to at least 2 NSAIDs, or&#xD;
             contraindication to NSAID therapy.&#xD;
&#xD;
          5. Subjects may be TNFα inhibitor-naïve or may have received up to 2 prior TNFα&#xD;
             inhibitor(s)..&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects have active fibromyalgia or total spinal ankylosis ('bamboo spine'), or any&#xD;
             other inflammatory arthritis.&#xD;
&#xD;
          2. Subjects have used medications in the manner as detailed by the exclusion criteria as&#xD;
             detailed in the study protocol.&#xD;
&#xD;
          3. Subjects have received technetium-99 conjugated with methylene diphosphonate other&#xD;
             than for diagnostic purpose within 5 years prior to baseline.&#xD;
&#xD;
          4. Have received any live (includes attenuated) vaccination within the 12 weeks prior to&#xD;
             the baseline.&#xD;
&#xD;
          5. Subjects have received any non-biological therapy for AS not listed as detailed in the&#xD;
             study protocol within or outside a clinical study in the 3 months or within 5&#xD;
             half-lives prior to the Baseline Visit (whichever is longer).&#xD;
&#xD;
          6. Subject has an active infection or history of infections&#xD;
&#xD;
          7. Have evidence of or test positive for hepatitis B virus (HBV)&#xD;
&#xD;
          8. Have evidence of or test positive for hepatitis C virus (HCV).&#xD;
&#xD;
          9. Have a historically positive human immunodeficiency virus (HIV) test or test positive&#xD;
             at screening for HIV.&#xD;
&#xD;
         10. Subjects have known tuberculosis (TB) infection, at high risk of acquiring TB&#xD;
             infection, or current or history of nontuberculous mycobacterium (NTMB) infection, or&#xD;
             LTB.&#xD;
&#xD;
         11. Have a history of a lymphoproliferative disorder including lymphoma or current signs&#xD;
             and symptoms suggestive of lymphoproliferative disease.&#xD;
&#xD;
         12. Subjects have active Crohn's disease (CD) or active ulcerative colitis (UC).&#xD;
&#xD;
         13. Subjects have active uveitis within 6 weeks prior to baseline.&#xD;
&#xD;
         14. Subjects have laboratory abnormalities at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sammy Zhu</last_name>
    <role>Study Director</role>
    <affiliation>Clinical medical director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April Ren</last_name>
    <phone>+86 21 67337035</phone>
    <email>rxd@inmagenebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Shen</last_name>
    <phone>+86 21 67337035</phone>
    <email>shenn@inmagenebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inmagene Biopharmaceuticals</name>
      <address>
        <city>Cayman Palms</city>
        <state>Grand Cayman</state>
        <zip>CAY</zip>
        <country>Cayman Islands</country>
      </address>
    </facility>
    <contact>
      <last_name>April Clinical study manager</last_name>
      <phone>+86 21 67337035</phone>
      <email>rxd@inmagenebio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Cayman Islands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

